Dylan P. Hartley

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Selective RET kinase inhibition for patients with RET-altered cancers

Vivek Subbiah, Vamsidhar Velcheti, Brian B. Tuch et al. · Annals of Oncology · 2018 · 429 citations · Full text

Medicine, Oncology, Pharmacology +16

The Hepatocellular Metabolism of 4-Hydroxynonenal by Alcohol Dehydrogenase, Aldehyde Dehydrogenase, and Glutathione S-Transferase

Dylan P. Hartley, James A. Ruth, Dennis R. Petersen · Archives of Biochemistry and Biophysics · 1995 · 243 citations

Life Sciences, Biochemistry, Pharmacology +17

Organ Distribution of Multidrug Resistance Proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and Hepatic Induction of Mrp3 by Constitutive Androstane Receptor Activators in Rats

Nathan J. Cherrington, Dylan P. Hartley, Ning Li et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 211 citations

Medicine, Biochemistry, Pharmacology +14

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra et al. · Clinical Cancer Research · 2014 · 211 citations

Medicine, Hematology, Pharmacology +17